سعر Lacosamet 50 mg 10 film-coated tablets 2026

Lacosamide 50 mg film-coated tablet, pack of 10 tablets; antiepileptic.

• Monotherapy of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.Population: Adults, adolescents and children from 2 yearsEuropean Medicines Agency (EMA) - EPAR product information
• Adjunctive therapy of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.Population: Adults, adolescents and children from 2 yearsEuropean Medicines Agency (EMA) - EPAR product information
• Adjunctive therapy of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.Population: Adults, adolescents and children from 4 yearsEuropean Medicines Agency (EMA) - EPAR product information

• Very common adverse reactions: dizziness, headache, nausea and diplopia.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information
• Common adverse reactions include depression, confusional state, insomnia, myoclonic seizures, ataxia, balance disorder, memory impairment, cognitive disorder, somnolence, tremor, nystagmus, paraesthesia, blurred vision, vertigo, tinnitus, vomiting, constipation, flatulence, dyspepsia, dry mouth, diarrhoea, pruritus, rash, muscle spasms, gait disturbance, asthenia, fatigue, irritability and falls.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information
• Serious reactions reported include AV block, bradycardia, atrial fibrillation/flutter, syncope, drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome/toxic epidermal necrolysis and agranulocytosis.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information

• Hypersensitivity to lacosamide or to any of the excipients.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information
• Known second- or third-degree atrioventricular (AV) block.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information

• Suicidal ideation and behaviour have been reported with antiepileptic drugs; patients should be monitored for signs of suicidal ideation and behaviours.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information
• Cardiac rhythm and conduction: lacosamide causes dose-related PR-interval prolongation; AV block, bradycardia, atrial fibrillation/flutter and serious ventricular tachyarrhythmia have been reported. Use with caution in patients with conduction problems, severe cardiac disease (e.g. myocardial ischaemia, heart failure) or on PR-prolonging drugs.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information
• Dizziness and ataxia may increase the risk of accidental injury or falls; patients should be cautious until familiar with the effects, and should not drive or operate machinery until they know how lacosamide affects them.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information

• PR-prolonging drugs (including sodium-channel blocking antiepileptics) and antiarrhythmicsUse with caution with medicinal products associated with PR prolongation (including sodium-channel blocking antiepileptics) and with antiarrhythmics; subgroup analyses did not show a greater PR prolongation with carbamazepine or lamotrigine.European Medicines Agency (EMA) - EPAR product information
• Strong CYP3A4 and CYP2C9 inhibitors (e.g. fluconazole, itraconazole, ketoconazole, ritonavir, clarithromycin)May moderately increase lacosamide exposure; use with caution, particularly in patients with renal or hepatic impairment.European Medicines Agency (EMA) - EPAR product information
• Strong enzyme inducers (e.g. rifampicin, St John's wort)May moderately reduce systemic exposure to lacosamide; start or stop these inducers with caution.European Medicines Agency (EMA) - EPAR product information

• Pregnancy: lacosamide should not be used during pregnancy unless clearly necessary; the risk of malformations in offspring of women treated with antiepileptics is 2-3 times that of the general population. Effective antiepileptic therapy should not be interrupted abruptly, as seizure worsening is harmful to mother and fetus; women of childbearing potential need specialist advice.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information
• Pregnancy (US label): available human data are insufficient to identify a drug-associated risk of major birth defects or miscarriage; lacosamide caused developmental toxicity (embryofetal and perinatal mortality, growth deficit) and developmental neurotoxicity in rats at clinically relevant exposures. Patients should be encouraged to enrol in the North American Antiepileptic Drug Pregnancy Registry.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Breast-feeding: lacosamide is excreted in human breast milk; a risk to the newborn/infant cannot be excluded and breast-feeding should be discontinued during treatment.International label, equivalent formulation · European Medicines Agency (EMA) - EPAR product information

• Lacosamide: Selectively enhances slow inactivation of voltage-gated sodium channels, stabilising hyperexcitable neuronal membranes; the precise antiepileptic mechanism in humans is not fully elucidated (EU SmPC section 5.1).